X Pharma Series |top| (2024)

“You’re going to stop feeding information to reporters, Lena. Not because I’ll hurt you—you’ve made it clear you don’t care about that. But because I’ll hurt him.” He tapped the folder. Inside: photos of David Park walking his mother to a dialysis clinic in Flushing. David’s little sister at a piano recital. David’s cat.

At its core, the Series is a library of chemically related compounds built around a proprietary scaffold (often a heterocyclic core or a constrained peptide macrocycle). Each iteration within the series—X-01, X-02, X-03, etc.—represents a specific mutation of functional groups designed to solve a distinct biological problem.

X-Pharma 102 – mRNA Regenerative Therapy x pharma series

The journalist died before the story could run. Hit-and-run. Brooklyn. No witnesses.

The series is noted for its "atmospheric" realism, using a cold, clinical visual palette to reflect the detached nature of corporate decision-making. By focusing on —the literal and metaphorical testing of a drug's "worth"—the story examines whether the healing of many justifies the exploitation of a few. “You’re going to stop feeding information to reporters,

“I’m a realist,” Marcus said. “Now step away from the cryovats, Lena. We have a Phase III to run.”

The X Pharma Series is characterized by several key features that distinguish it from traditional pharmaceutical development and manufacturing approaches. Some of the most significant features include: Inside: photos of David Park walking his mother

The Science of Bioavailability: Why the "Series" Approach Works